- Home
- OZ vs NLSP Comparison
OZ vs NLSP Comparison
Compare OZ & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OZ
- NLSP
- Stock Information
- Founded
- OZ 2020
- NLSP 2015
- Country
- OZ United States
- NLSP Switzerland
- Employees
- OZ N/A
- NLSP N/A
- Industry
- OZ
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- OZ
- NLSP Health Care
- Exchange
- OZ Nasdaq
- NLSP Nasdaq
- Market Cap
- OZ 234.8M
- NLSP 12.4M
- IPO Year
- OZ N/A
- NLSP 2021
- Fundamental
- Price
- OZ $63.00
- NLSP $1.57
- Analyst Decision
- OZ
- NLSP
- Analyst Count
- OZ 0
- NLSP 0
- Target Price
- OZ N/A
- NLSP N/A
- AVG Volume (30 Days)
- OZ 3.5K
- NLSP 886.4K
- Earning Date
- OZ 11-19-2025
- NLSP 10-06-2025
- Dividend Yield
- OZ N/A
- NLSP N/A
- EPS Growth
- OZ N/A
- NLSP N/A
- EPS
- OZ N/A
- NLSP N/A
- Revenue
- OZ $5,695,000.00
- NLSP N/A
- Revenue This Year
- OZ N/A
- NLSP N/A
- Revenue Next Year
- OZ N/A
- NLSP N/A
- P/E Ratio
- OZ N/A
- NLSP N/A
- Revenue Growth
- OZ 235.00
- NLSP N/A
- 52 Week Low
- OZ $56.77
- NLSP $1.30
- 52 Week High
- OZ $82.89
- NLSP $5.40
- Technical
- Relative Strength Index (RSI)
- OZ 42.36
- NLSP 36.10
- Support Level
- OZ $63.00
- NLSP $1.60
- Resistance Level
- OZ $64.34
- NLSP $1.73
- Average True Range (ATR)
- OZ 0.53
- NLSP 0.12
- MACD
- OZ -0.14
- NLSP -0.02
- Stochastic Oscillator
- OZ 48.11
- NLSP 22.06
About OZ Belpointe PREP LLC Units
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.